Anika Therapeutics
ANIK
161 hedge funds and large institutions have $554M invested in Anika Therapeutics in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 61 increasing their positions, 46 reducing their positions, and 27 closing their positions.
246% more call options, than puts
Call options by funds: $6.59M | Put options by funds: $1.91M
33% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 46
24% more capital invested
Capital invested by funds: $446M → $554M (+$108M)
4.42% less ownership
Funds ownership: 94.54% → 90.12% (-4.4%)
5% less funds holding
Funds holding: 170 → 161 (-9)
30% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$6.17M |
| 2 |
EC
Engaged Capital
Newport Beach,
California
|
+$4.91M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$3.38M |
| 4 |
BlackRock
New York
|
+$3.1M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$16.5M |
| 2 |
Bank of New York Mellon
New York
|
-$8.61M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.98M |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$5.72M |
| 5 |
First Manhattan
New York
|
-$3.27M |
ANIK Hedge Fund Activity: Q3 2018 in Review
161 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q3 2018, worth a combined $554M — up 24% from $446M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ANIK and 19 opened new positions — a net loss of 8 holders — while 46 trimmed existing stakes and 61 added.
The largest buyer was State Street, adding an estimated $6.17M. The largest seller was Morgan Stanley, cutting an estimated $16.5M.
- 161 institutional investors held Anika Therapeutics (ANIK) as of Q3 2018, down from 170 in Q2 2018.
- Funds reported $554M of Anika Therapeutics stock for Q3 2018, up 24% quarter-over-quarter.
- 19 funds opened new Anika Therapeutics positions in Q3 2018 and 27 closed out, a net change of -8 holders.
- The largest Anika Therapeutics buyer in Q3 2018 was State Street, an estimated $6.17M added.
- The largest Anika Therapeutics seller in Q3 2018 was Morgan Stanley, an estimated $16.5M sold.
Based on aggregated 13F filings for Q3 2018.